Celularity Inc. (NASDAQ:CELU) Short Interest Update

Celularity Inc. (NASDAQ:CELU) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 395,600 shares, an increase of 7.1% from the December 31st total of 369,300 shares. Currently, 4.2% of the company’s stock are short sold. Based on an average trading volume of 1,080,000 shares, the short-interest ratio is presently 0.4 days.

Celularity Stock Down 0.2 %

Shares of Celularity stock traded down $0.01 during trading hours on Tuesday, reaching $2.02. 22,412 shares of the company were exchanged, compared to its average volume of 71,475. The stock’s fifty day moving average is $2.23 and its 200 day moving average is $2.56. Celularity has a 1 year low of $1.30 and a 1 year high of $7.97.

Celularity (NASDAQ:CELU) last issued its quarterly earnings results on Friday, December 6th. The company reported ($0.73) earnings per share for the quarter. Celularity had a negative return on equity of 119.53% and a negative net margin of 72.72%.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.